We are a clinical-stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. Our lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders.
We are currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Our mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.
|Address||1951 NW 7th Avenue, Suite 520 Miami, Florida 33136|
|Phone Number||(305) 909-0840|
|View Prospectus:||Longeveron LLC|
|Revenues||$6.29 mil (last 12 months)|
|Net Income||$-2.8 mil (last 12 months)|
|Price range||$10.00 - $10.00|
|Est. $ Volume||$26.6 mil|
|Manager / Joint Managers||EF Hutton|
|Expected To Trade:||2/12/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|